secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001193125-23-036914
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma reports $275M cash as of Dec 31, 2022; updates corporate presentation
--------------------------------------------------------------------------------

- Cash and securities of approximately $275 million as of December 31, 2022.
- Updated corporate presentation (Exhibit 99.1) highlights needle-free epinephrine solution for allergic reactions.
- No additional financial results, guidance, or operational milestones disclosed in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523036914/0001193125-23-036914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523036914/d430763d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-036914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer